Unlike previous studies only analysing patients with prostate cancer and/or healthy individuals [43,83], Turan et al. [84] analysed PSA levels in three groups: patients with prostate cancer, patients with benign prostatic hyperplasia and healthy individuals (control). This evidence concerns the gene KLK3 and benign prostatic hyperplasia.